Payment overview · 2025
General Payments
$463.50
21 reported records · 11 companies
Healthcare provider profile · identity verified
Ginger W Mcdougal, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · MONTGOMERY, AL · NPI 1699077834
Verified facts
What the public records show
CMS Open Payments records show Ginger W Mcdougal, CRNP received $463.50 in general payments during 2025 across 21 reported records.
Merck Sharp & Dohme LLC accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $96.21 | 20.8% | 4 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $73.70 | 15.9% | 4 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $56.77 | 12.2% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.42 | 10.4% | 2 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $44.93 | 9.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.33 | 9.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$31.73 | 6.8% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $20.19 | 4.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.57 | 3.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.17 | 3.5% | 1 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $14.48 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $463.50 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $96.21 | 4 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $57.93 | 3 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $57.93 | 3 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $44.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| DERMABOND PRINEO Normalized: dermabond prineo |
Device | Ethicon US, LLC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| QUIKCLOT Normalized: quikclot |
Device | Teleflex LLC | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| SpyGlass Discover Normalized: spyglass discover |
Device | Boston Scientific Corporation | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Endopath Normalized: endopath |
Device | Ethicon US, LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 182 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 113 | 38 |
| Losartan Potassium | Losartan Potassium | 101 | 28 |
| Lisinopril | Lisinopril | 100 | 31 |
| Trazodone Hcl | Trazodone Hcl | 96 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 33 |
| Omeprazole | Omeprazole | 90 | 27 |
| Mounjaro | Tirzepatide | 80 | 15 |
| Sertraline Hcl | Sertraline Hcl | 77 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 26 |
| Jardiance | Empagliflozin | 75 | 12 |
| Meloxicam | Meloxicam | 72 | 27 |
| Azithromycin | Azithromycin | 71 | 56 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 52 |
| Ozempic | Semaglutide | 68 | 14 |
| Montelukast Sodium | Montelukast Sodium | 64 | 23 |
| Metformin Hcl | Metformin Hcl | 61 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 18 |
| Methylprednisolone | Methylprednisolone | 45 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 14 |
| Famotidine | Famotidine | 42 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Furosemide | Furosemide | 38 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 27 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 24 |
| Methocarbamol | Methocarbamol | 32 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 14 |
| Carvedilol | Carvedilol | 30 | 13 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 16 |
| Allopurinol | Allopurinol | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Simvastatin | Simvastatin | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Bupropion Xl | Bupropion Hcl | 22 | 11 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 12 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $463.50 · 21 records | Merck Sharp & Dohme LLC | DERMABOND PRINEO, Da Vinci Surgical System, ETHICON, Endopath, GATTEX, JOURNAVX, Ozempic, QUIKCLOT, Rybelsus, STRATAFIX, SURGICEL NU-KNIT, SURGIFLO Hemostatic Matrix, SpyGlass Discover, URGOCLEAN AG, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VENASEAL, VISTASEAL, ZERBAXA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error